title: NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
abstract: BACKGROUND
  Myxoid/round cell liposarcoma (MRCL) is the second most common liposarcoma subtype, accounting for >33% of liposarcomas and approximately 10% of all soft tissue sarcomas. Although MRCL is a chemosensitive subtype, patients with metastatic disease have a poor outcome. NY-ESO-1 is a cancer-testis antigen (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T-cell therapy trials for the treatment of several solid tumors.
  
  
  METHODS
  The authors investigated the feasibility of targeting NY-ESO-1 in patients with MRCL by evaluating the prevalence of NY-ESO-1 expression in tumors using immunohistochemistry and quantitative reverse transcriptase-polymerase chain reaction analysis. NY-ESO-1-specific tumor recognition by NY-ESO-1-specific T-cells also was analyzed using a chromium release assay.
  
  
  RESULTS
  A search of the University of Washington Sarcoma Tissue Bank identified paraffin-embedded tumor samples from 25 patients with MRCL. NY-ESO-1 expression was observed in every MRCL tumor assessed (100%); in 18 tumors (72%), staining was homogenous. In all but 2 tumors, staining was sufficiently robust (2+) that such patients would be eligible for clinical trials of NY-ESO-1-directed therapy. By using NY-ESO-1 specific, CD8-positive T-cells, the in vitro sensitivity of myxoid liposarcoma cell lines to antigen-specific lysis was demonstrated.
  
  
  CONCLUSIONS
  The current results establish NY-ESO-1 as an important target antigen for the treatment of patients with MRCL.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA, USA. spollack@fhcrc.org
authors.forename: Seth M
authors.initials: SM
authors.lastname: Pollack
authors.forename: Achim A
authors.initials: AA
authors.lastname: Jungbluth
authors.forename: Benjamin L
authors.initials: BL
authors.lastname: Hoch
authors.forename: Erik A
authors.initials: EA
authors.lastname: Farrar
authors.forename: Marie
authors.initials: M
authors.lastname: Bleakley
authors.forename: David J
authors.initials: DJ
authors.lastname: Schneider
authors.forename: Elizabeth T
authors.initials: ET
authors.lastname: Loggers
authors.forename: Eve
authors.initials: E
authors.lastname: Rodler
authors.forename: Janet F
authors.initials: JF
authors.lastname: Eary
authors.forename: Ernest U
authors.initials: EU
authors.lastname: Conrad
authors.forename: Robin L
authors.initials: RL
authors.lastname: Jones
authors.forename: Cassian
authors.initials: C
authors.lastname: Yee
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D045744:Cell Line, Tumor; D006801:Humans; D007150:Immunohistochemistry; D007167:Immunotherapy; D018208:Liposarcoma, Myxoid / Q000276:immunology* / Q000628:therapy*; D008565:Membrane Proteins / Q000032:analysis / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D008565:Membrane Proteins